Next-Generation Therapeutics
Sanyo Biotech harnesses the power of genomic medicine and AI-driven drug discovery to develop transformative therapies for patients with serious unmet medical needs.
Our Heritage
In 1906, Takeshi Oka - a young pharmacologist from Osaka - founded a small research laboratory dedicated to isolating natural compounds from Japanese medicinal plants. What began as a modest family endeavor would grow into one of the most enduring names in biotechnology.
For four generations, the Oka family has guided Sanyo through every era of modern medicine - from early herbal extracts and fermentation science in pre-war Japan, to pioneering work in antibiotics during the 1950s, to the molecular biology revolution of the late 20th century.
Today, under the stewardship of the fourth generation, Sanyo Biotech honors its founder's original mission: to harness nature's intelligence for human healing - now powered by genomics, AI, and precision medicine.
About Sanyo Today
Headquartered in Cambridge, MA with R&D roots still in Osaka, Sanyo Biotech combines 120 years of pharmaceutical heritage with cutting-edge biological science to develop transformative therapies for patients with serious unmet medical needs.
Our interdisciplinary team spans three continents, blending deep expertise in structural biology, computational chemistry, and clinical development to accelerate the path from discovery to the clinic.
Our Science
Our platform integrates proprietary technologies across computational biology, targeted delivery, and translational medicine.
Our proprietary machine learning models analyze multi-omic datasets to identify novel drug targets with unprecedented precision and speed.
Engineered delivery vehicles enable tissue-specific targeting of nucleic acid therapeutics, maximizing efficacy while minimizing off-target effects.
Companion diagnostics and real-world evidence inform every stage of clinical development, enabling smarter trial design and patient stratification.
Pipeline
A diversified portfolio spanning oncology, immunology, and rare genetic diseases.
| Program | Indication | Modality | Stage |
|---|---|---|---|
| SYO-101 | Non-Small Cell Lung Cancer | mRNA Therapeutic | Phase II |
| SYO-205 | Triple-Negative Breast Cancer | Antibody-Drug Conjugate | Phase I |
| SYO-310 | Systemic Lupus Erythematosus | Small Molecule | Phase II |
| SYO-412 | Spinal Muscular Atrophy | Gene Therapy | Phase I |
| SYO-508 | Idiopathic Pulmonary Fibrosis | siRNA | Preclinical |
| SYO-603 | Acute Myeloid Leukemia | Bispecific Antibody | Phase III |
Non-Small Cell Lung Cancer · mRNA Therapeutic
Phase IITriple-Negative Breast Cancer · ADC
Phase ISystemic Lupus Erythematosus · Small Molecule
Phase IISpinal Muscular Atrophy · Gene Therapy
Phase IIdiopathic Pulmonary Fibrosis · siRNA
PreclinicalAcute Myeloid Leukemia · Bispecific Antibody
Phase IIILeadership
Our leadership team brings decades of experience from leading biotech and pharmaceutical organizations.
4th generation heir to the Oka family legacy. Leading Sanyo into its next century of innovation.
Former VP at Genentech. 20+ years in drug development.
Pioneer in mRNA therapeutics. Nature published researcher.
Former Goldman Sachs healthcare banker. IPO specialist.
Board-certified oncologist. Led 15+ clinical trials at FDA.
Newsroom
Stay current with Sanyo's breakthroughs, partnerships, and milestones.
Statistically significant improvement in overall survival demonstrated in patients with relapsed/refractory acute myeloid leukemia.
Read More →
Multi-year agreement to co-develop next-generation antibody-drug conjugates for solid tumors worth up to $1.2B.
Read More →
Oversubscribed round led by SoftBank Vision Fund and Flagship Pioneering, bringing total funding to $2.4B.
Read More →Get In Touch
Whether you're a potential partner, investor, or patient advocate, we'd love to hear from you.
200 Technology Square
Cambridge, MA 02139
+1 (617) 555-0142